Lexicon Pharmaceuticals vs Scilex
LXRX and SCLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LXRX and SCLX compare
Lexicon Pharmaceuticals is the larger company, worth 59 times as much as Scilex ($810M against $13.8M).
Scilex grew revenue faster over the last twelve months (−28.5% versus −45.6% for Lexicon Pharmaceuticals).
Lexicon Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −162% compared with −1470% at Scilex.
Lexicon Pharmaceuticals scores higher on the StockData Score (5 against 1 for Scilex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LXRX | SCLX |
|---|---|---|
| Size and price | ||
| Market cap | $810M | $13.8M |
| Share price | $1.82 | $1.62 |
| Change, 1 year | 16.7% | −91.2% |
| Change, 5 years | −63.3% | −99.5% |
| Beta (5Y) | 1.76 | 0.81 |
| Employees | 81 | 34 |
| StockData Score | ||
| Total score | 5 (better) | 1 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 2 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 21.0× | 0.4× (better) |
| P/B | 4.9× | – |
| Fair value | $0.882 | – |
| Margin of safety | −106% | – |
| Growth | ||
| Revenue growth (TTM) | −45.6% | −28.5% (better) |
| Revenue growth, 5Y average | 15.7% (better) | 5.1% |
| Profitability | ||
| Gross margin | 98.9% | 161% (better) |
| Operating margin | −147% (better) | −1136% |
| Net margin | −162% (better) | −1470% |
| Return on equity | −43.9% | – |
| Return on invested capital | −140% | – |
| Financial health | ||
| Debt / equity | 0.32 | – |
| Interest coverage | – | −22.2× |
| Current ratio | 10.63 (better) | 0.07 |
| Altman Z-score | −5.49 (better) | −12.74 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | −8.7% | – |
| Shareholder yield | −8.7% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 81.9% | 9.8% |
| Insider net buying, 12 months | $2.8M (better) | −$12.8M |
Go deeper
- LXRX stock overview
- LXRX income statement
- LXRX valuation and score
- SCLX stock overview
- SCLX income statement
- SCLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.